Dyslipidemia Ldl Treatment Goals 2026

---
name: dyslipidemia-ldl-treatment-goals-2026
description: Set absolute LDL-C, non-HDL-C, and ApoB treatment goals, PLUS percent LDL-C reduction, for a primary-prevention patient on lipid-lowering therapy per the re-introduced treatment goals in the 2026 ACC/AHA multisociety dyslipidaemia guideline. Covers goals by PREVENT-ASCVD category (low / borderline / intermediate / high), by CAC score, in severe hypercholesterolaemia / FH, in diabetes with multiple ASCVD risk factors, and the ApoB targets once LDL-C and non-HDL-C goals are met. Use when a clinician asks what LDL goal to aim for, LDL target for intermediate risk, non-HDL goal, ApoB target, dual goals on statin, patient at goal or not, how low should LDL go, statin not enough what next. Grounded in the 2026 ACC/AHA multisociety dyslipidaemia guideline.
---

# Dyslipidaemia LDL-C, Non-HDL-C, ApoB Treatment Goals (2026)

The 2026 guideline **re-introduces absolute treatment goals** — a major change from 2018, which had largely moved away from goals. Treatment is now anchored to both **absolute goals AND % LDL reduction**, with ApoB as a secondary target.

---

## Step 1 — Identify the patient's goal category

The treatment goal depends on **why** the patient is on LLT. Match to one of these groups:

| Group | Trigger | Default goal (before CAC) |
|---|---|---|
| **Severe hypercholesterolaemia** — no other risk factors | LDL-C ≥190 mg/dL | **LDL <100 mg/dL** |
| **Severe hypercholesterolaemia + clinical / genetic FH** | LDL-C ≥190 mg/dL + FH criteria | **LDL <70 mg/dL** (non-HDL <100) + **≥50% LDL reduction** |
| **Baseline LDL 70–189 mg/dL + low 10-year risk (<3%)** | PREVENT <3% but LLT chosen for other reasons (LDL ≥160, 30-yr risk ≥10%, strong FH, high Lp(a)) | **LDL <100 mg/dL** (non-HDL <130) + **≥30% reduction** |
| **Baseline LDL 70–189 mg/dL + borderline (3–<5%)** | On LLT after enhancer / CAC assessment | **LDL <100 mg/dL** (non-HDL <130) + **≥30% reduction** |
| **Baseline LDL 70–189 mg/dL + intermediate (5–<10%)** | Class 1 moderate-to-high-intensity statin | **LDL <100 mg/dL** (non-HDL <130) + **≥30–50% reduction** (≥50% at the higher end of intermediate) |
| **Baseline LDL 70–189 mg/dL + high (≥10%)** | Class 1 high-intensity statin | **LDL <70 mg/dL** (non-HDL <100) + **≥50% reduction** |
| **Diabetes mellitus age 40–75, no clinical ASCVD** | Class 1 LLT | **LDL <100 mg/dL** (≥30–49% reduction); non-HDL **<130 mg/dL** |
| **Diabetes + multiple ASCVD risk factors** | Class 1 high-intensity LLT | **LDL <70 mg/dL** (≥50% reduction); non-HDL **<100 mg/dL** |

---

## Step 2 — Modify the goal by CAC score (if performed)

CAC scores further sharpen the LDL and non-HDL goals:

| CAC score (AU) | LDL-C goal | Non-HDL-C goal | ApoB goal (if measured) |
|---|---|---|---|
| **0** | Treatment usually deferred; if treated, baseline goal applies | Baseline | — |
| **1–99** (or <75th percentile) | **<100 mg/dL** (≥30% reduction) | **<130 mg/dL** | **<90 mg/dL** |
| **100–299** (or ≥75th percentile, or moderate-to-severe incidental CAC) | **<70 mg/dL** (≥50% reduction) | **<100 mg/dL** | **<70 mg/dL** |
| **≥300** | **<70 mg/dL** (≥50% reduction) | **<100 mg/dL** | **<70 mg/dL** |
| **≥1000** | **<55 mg/dL** | **<85 mg/dL** | **<55 mg/dL** |

Use the **lower (more stringent) of** the baseline category goal AND the CAC-modified goal.

---

## Step 3 — Add ApoB goals once LDL-C and non-HDL-C are met

ApoB is a direct measure of atherogenic particle number. The guideline recommends ApoB testing **(Class 2)** in adults on LLT with any of:

- **Concomitant ASCVD**
- **Diabetes mellitus**
- **Cardiovascular-kidney-metabolic (CKM) syndrome**
- **Elevated triglycerides** (≥200 mg/dL)

In these groups, once LDL-C and non-HDL-C goals are achieved, use the ApoB target to guide **further intensification**:

| LDL-C target achieved | ApoB target |
|---|---|
| <100 mg/dL | **<90 mg/dL** |
| <70 mg/dL | **<70 mg/dL** |
| <55 mg/dL | **<55 mg/dL** |

ApoB discordance from LDL-C (i.e. LDL-C at goal but ApoB high) → **intensify LLT** per the ApoB goal.

---

## Step 4 — Monitor and verify goal achievement

- **4–12 weeks** after starting, intensifying, or changing LLT → repeat lipid panel
- **Every 6–12 months** thereafter once stable
- At each visit confirm:
  - Current LDL-C vs goal (absolute)
  - % LDL reduction from pre-treatment baseline
  - Non-HDL-C vs goal
  - If applicable, ApoB vs goal
  - Adherence, muscle symptoms, LFTs if clinically indicated
  - CPK **only** if severe myalgia / weakness (not routine)
  - Coenzyme Q10 **not recommended** as routine prophylaxis
  - Aminotransferase monitoring **not routine** once stable

---

## Step 5 — If goals not met, add non-statin therapy

Preferred add-on sequence (adapted from Table 2 of the guideline):

| Agent | Expected additional LDL reduction |
|---|---|
| **Ezetimibe** 10 mg oral daily | ~25% add-on (~20% monotherapy) |
| **PCSK9 mAb** — alirocumab, evolocumab SC q2–4 wk | ~45–65% |
| **Inclisiran** SC — initial, then 3 months, then q6mo | ~50% |
| **Bempedoic acid** oral daily | ~15–20% add-on (~20–25% monotherapy) |
| **Bile acid sequestrant** (cholestyramine, colesevelam, colestipol) | ~10–30% (**may ↑ TG**) |
| **Lomitapide** oral daily | ~40–50% (REMS program; HoFH only) |
| **Evinacumab** IV q4wk | ~50% (HoFH / severe) |

**Typical escalation path:**
1. Maximally-tolerated statin
2. + Ezetimibe
3. + PCSK9 mAb or inclisiran
4. + Bempedoic acid in statin-intolerant or inadequate response
5. Bile acid sequestrant (avoid if TG elevated)
6. Lomitapide / evinacumab for severe FH

---

## Guardrails

- **The 2026 guideline uses dual goals** — absolute AND percent reduction. Meeting the absolute goal with only a 15% reduction from baseline in a high-risk patient is NOT at goal
- **Treat to goal, not just "start a statin"** — the 2018 approach of "start a statin and move on" is superseded
- **ApoB is especially informative in LDL/non-HDL discordance** — a patient with LDL at goal but ApoB >90 (goal <90) has residual atherogenic particle burden and needs intensification
- **Non-HDL-C captures ALL atherogenic lipoproteins** (LDL + VLDL + Lp(a)) — do not ignore non-HDL in favour of LDL alone, especially in high-TG patients
- **FH / LDL ≥190** has its own stringent goals **regardless of 10-year PREVENT-ASCVD** — a young adult with LDL 200 and 10-year risk 2% still needs ≥50% LDL reduction and goal <70
- **DM + multiple ASCVD risk factors** moves the goal from <100 to <70 — identify these patients proactively
- **Lifestyle optimisation is NOT replaced by LLT** — diet, exercise ≥150 min/wk, weight management, tobacco abstinence, sleep remain Class 1
- **Dietary supplements (garlic, turmeric, red yeast rice, non-prescription fish oil) are NOT recommended** for dyslipidaemia management per the guideline
- **Do NOT re-check CAC routinely once on LLT** — statins can paradoxically increase CAC density by stabilising plaque; serial CAC in treated patients is not a monitoring tool
- **CPK testing** is only indicated for severe myalgia or weakness, with cessation if levels ≥10 × ULN
- **Routine aminotransferase monitoring** is not needed once stable

---

## Related MD2SKILL skills

- `prevent-ascvd-risk-calculator-interpretation` — the risk score that defines the goal category
- `dyslipidemia-cpr-framework-2026` — the full workflow leading to this goal-setting step
- `cac-scoring-indication-interpretation-2026` — CAC-modified goals
- `lpa-screening-interpretation-cascade` — Lp(a) measurement and its interaction with goal-setting
- `bemdec-prescribing-guide` — bempedoic acid for statin-intolerant or add-on therapy

---

## Sources

**Primary:** 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Multisociety Guideline on the Management of Dyslipidaemia.

**Review used for extraction:** Abramov D et al. **Primary Prevention of Dyslipidemia: 10 Practice-Changing Takeaways from the 2026 ACC/AHA Multisociety Guideline.** *Current Atherosclerosis Reports.* 2026;28:63. DOI: 10.1007/s11883-026-01437-9. Sections "Key Message 8: Treatment-Statins", "Key Message 9: Dyslipidemia Treatment Goals", and Tables 1 & 2.